

Roberta Mazzieri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4871787/roberta-mazzieri-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40
papers

4,445
citations

26
h-index

40
g-index

40
ext. papers

4,922
ext. citations

9.5
avg, IF

4.82
L-index

#	Paper	IF	Citations
40	Frontiers in the treatment of glioblastoma: Past, present and emerging. <i>Advanced Drug Delivery Reviews</i> , 2021 , 171, 108-138	18.5	29
39	Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma. <i>Nanoscale</i> , 2021 , 13, 16909-16922	7.7	4
38	A novel add-on collimator for preclinical radiotherapy applications using a standard cell irradiator: design, construction, and validation. <i>Medical Physics</i> , 2020 , 47, 2461-2471	4.4	2
37	B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity. <i>Oncot Immunology</i> , 2018 , 7, e1393599	7.2	10
36	Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma. <i>Biomaterials</i> , 2018 , 171, 230-246	15.6	27
35	Immune system augmentation via humanization using stem/progenitor cells and bioengineering in a breast cancer model study. <i>International Journal of Cancer</i> , 2018 , 143, 1470-1482	7.5	23
34	Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1971-1984	15.9	42
33	Interleukin-23 regulates interleukin-17 expression in wounds, and its inhibition accelerates diabetic wound healing through the alteration of macrophage polarization. <i>FASEB Journal</i> , 2018 , 32, 2086-2094	0.9	21
32	Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance. <i>Frontiers in Oncology</i> , 2018 , 8, 322	5.3	84
31	Engineering a humanized bone organ model in mice to study bone metastases. <i>Nature Protocols</i> , 2017 , 12, 639-663	18.8	74
30	Translational Significance for Tumor Metastasis of Tumor-Associated Macrophages and Epithelial-Mesenchymal Transition. <i>Frontiers in Immunology</i> , 2017 , 8, 1106	8.4	41
29	Angiopoietin 2 expression in the cornea and its control of corneal neovascularisation. <i>British Journal of Ophthalmology</i> , 2016 , 100, 1005-1010	5.5	6
28	Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1. <i>Cancer Research</i> , 2015 , 75, 4895-909	10.1	8
27	Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. <i>Cancer Cell</i> , 2015 , 28, 225-233	24.3	80
26	Emergence of Fc-Gamma-Riib-Dominance Contributes to Resistance to Therapeutic Antibodies in Patients with Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2015 , 126, 447-447	2.2	
25	Targeted genome editing in human repopulating haematopoietic stem cells. <i>Nature</i> , 2014 , 510, 235-240	50.4	420
24	Genetic engineering of hematopoiesis for targeted IFN- β delivery inhibits breast cancer progression. <i>Science Translational Medicine</i> , 2014 , 6, 217ra3	17.5	71

23	Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon- α activates immunity and inhibits breast cancer progression. <i>OncImmunology</i> , 2014 , 3, e28696	7.2	11
22	A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. <i>Blood</i> , 2013 , 122, 243-52	2.2	86
21	Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. <i>Cancer Cell</i> , 2011 , 19, 512-26	24.3	464
20	Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. <i>Cancer Cell</i> , 2008 , 14, 299-311	24.3	215
19	Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 18758-63	11.5	83
18	A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts. <i>Oncogene</i> , 2007 , 26, 725-32	9.2	13
17	Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. <i>Blood</i> , 2007 , 109, 5276-85	2.2	398
16	An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. <i>Molecular Biology of the Cell</i> , 2006 , 17, 367-78	3.5	60
15	Hypomorphic mutation of the TALE gene Prep1 (pKnox1) causes a major reduction of Pbx and Meis proteins and a pleiotropic embryonic phenotype. <i>Molecular and Cellular Biology</i> , 2006 , 26, 5650-62	4.8	82
14	Expression of truncated latent TGF-beta-binding protein modulates TGF-beta signaling. <i>Journal of Cell Science</i> , 2005 , 118, 2177-87	5.3	36
13	The urokinase receptor and the regulation of cell proliferation. <i>Thrombosis and Haemostasis</i> , 2005 , 93, 641-6	7	32
12	Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. <i>Journal of Biological Chemistry</i> , 2003 , 278, 2750-7	5.4	420
11	Measurement of active TGF-beta generated by cultured cells. <i>Methods in Molecular Biology</i> , 2000 , 142, 13-27	1.4	23
10	Proteolytic control of growth factor availability. <i>Apms</i> , 1999 , 107, 80-5	3.4	132
9	Latent transforming growth factor-beta: structural features and mechanisms of activation. <i>Kidney International</i> , 1997 , 51, 1376-82	9.9	392
8	Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. <i>EMBO Journal</i> , 1997 , 16, 2319-32	13	319
7	TGF-beta latency: biological significance and mechanisms of activation. <i>Stem Cells</i> , 1997 , 15, 190-7	5.8	212
6	Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells. <i>Journal of Cellular Physiology</i> , 1996 , 169, 300-8	7	9

5	Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta1. <i>Journal of Biological Chemistry</i> , 1996 , 271, 29891-6	5-4	118
4	Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. <i>Journal of Biological Chemistry</i> , 1995 , 270, 9709-16	5-4	210
3	Urokinase and urokinase receptor expression in somatic cell hybrids. <i>Fibrinolysis</i> , 1994 , 8, 344-352		9
2	Assignment of the human urokinase receptor gene (PLAUR) to 19q13. <i>Cytogenetic and Genome Research</i> , 1992 , 60, 197-9	1-9	7
1	Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. <i>Journal of Cell Biology</i> , 1991 , 113, 1193-201	7-3	172